Buscar
Alumis Inc
ALMSAñadir a la lista de seguimiento
25.310USD
+0.900+3.69%
Cierre 08-14 16:00（ET）Cotizaciones retrasadas 15 min
3.22BCap. mercado
PérdidaP/E TTM
Más Datos de Alumis Inc Compañía
Alumis Inc. is a late-stage biopharmaceutical company. The Company is engaged in developing next-generation targeted therapies with the potential to significantly improve patient health and outcomes across a range of immune-mediated diseases. Leveraging its proprietary data analytics platform and precision approach, the Company is developing a pipeline of oral tyrosine kinase 2 (TYK2) inhibitors, consisting of ESK-001 for the treatment of systemic immune-mediated disorders, such as moderate-to-severe plaque psoriasis and systemic lupus erythematosus, and A-005 for the treatment of neuroinflammatory and neurodegenerative diseases such as multiple sclerosis and Parkinson’s Disease. In addition, its pipeline also includes lonigutamab, a subcutaneously delivered anti-insulin-like growth factor 1 receptor therapy for the treatment of thyroid eye disease, as well as several preclinical programs identified through this precision approach.
Perfil de Alumis Inc
Símbolo de cotizaciónALMS
Nombre de la empresaAlumis Inc
Fecha de salida a bolsaJun 28, 2024
Director ejecutivoBabler (Martin)
Número de empleados168
Tipo de seguridadOrdinary Share
Fin del año fiscalJun 28
Dirección280 East Grand Avenue
CiudadSOUTH SAN FRANCISCO
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal94080
Teléfono16502316625
Sitio Webhttps://www.alumis.com/
Símbolo de cotizaciónALMS
Fecha de salida a bolsaJun 28, 2024
Director ejecutivoBabler (Martin)
Ejecutivos de Alumis Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Martin Babler
Mr. Martin Babler
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
110.49K
--
Mr. Martin Babler
Mr. Martin Babler
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
110.49K
--
Mr. Mark Bradley
Mr. Mark Bradley
Chief Development Officer
Chief Development Officer
46.16K
-5.57%
Mr. Mark Bradley
Mr. Mark Bradley
Chief Development Officer
Chief Development Officer
46.16K
-5.57%
Mr. Derrick Richardson
Mr. Derrick Richardson
Senior Vice President - People and Culture
Senior Vice President - People and Culture
42.80K
--
Dr. Jorn Drappa, M.D., Ph.D.
Dr. Jorn Drappa, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
28.44K
-8.60%
Dr. Jorn Drappa, M.D., Ph.D.
Dr. Jorn Drappa, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
28.44K
-8.60%
Mr. John R. Schroer
Mr. John R. Schroer
Chief Financial Officer
Chief Financial Officer
24.72K
-13.28%
Mr. John R. Schroer
Mr. John R. Schroer
Chief Financial Officer
Chief Financial Officer
24.72K
-13.28%
Mr. Patrick (Pat) Machado, J.D.
Mr. Patrick (Pat) Machado, J.D.
Independent Director
Independent Director
10.62K
+33.47%
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Martin Babler
Mr. Martin Babler
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
110.49K
--
Mr. Martin Babler
Mr. Martin Babler
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
110.49K
--
Mr. Mark Bradley
Mr. Mark Bradley
Chief Development Officer
Chief Development Officer
46.16K
-5.57%
Mr. Mark Bradley
Mr. Mark Bradley
Chief Development Officer
Chief Development Officer
46.16K
-5.57%
Mr. Derrick Richardson
Mr. Derrick Richardson
Senior Vice President - People and Culture
Senior Vice President - People and Culture
42.80K
--
Dr. Jorn Drappa, M.D., Ph.D.
Dr. Jorn Drappa, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
28.44K
-8.60%
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Alumis Inc?
Los cinco principales accionistas de Alumis Inc son: Mr. Martin Babler
¿Cuántas instituciones poseen acciones de Alumis Inc (ALMS)?
A fecha de 2026Q1, 276 instituciones poseen acciones de Alumis Inc, con un valor de mercado combinado de aproximadamente 100.94M, lo que representa el 82.61% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en 21401178.00.